1. Volume 145, Issue 1, Pages 87-95 (July 2013)
Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry 
Rehan J. Haidry, Jason M. Dunn, Mohammed A. Butt, Matthew G. Burnell, Abhinav Gupta, Sarah Green, Haroon Miah, Howard L. Smart, Pradeep Bhandari, Lesley Ann Smith, Robert Willert, Grant Fullarton, John Morris, Massimo Di Pietro, Charles Gordon, Ian Penman, Hugh Barr, Praful Patel, Philip Boger, Neel Kapoor, Brinder Mahon, Jonathon Hoare, Ravi Narayanasamy, Dermot O'Toole, Edward Cheong, Natalie C. Direkze, Yeng Ang, Marco Novelli, Matthew R. Banks, Laurence Bruce Lovat 
Gastroenterology 
Volume 145, Issue 1, Pages (July 2013)
DOI: /j.gastro
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Primary outcomes of complete eradication of HGD, LGD, all dysplasia and Barrett's esophagus in 335 patients who have completed treatment protocol at 12 months. Twelve patients underwent ablation for LGD.
Gastroenterology  , 87-95DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
KM analysis for durability of CR-D and CR-BE after successful treatment where patients underwent both focal and circumferential ablation during the 12-month protocol. Time 0 represents the first biopsy demonstrating no dysplasia or no intestinal metaplasia (BE) and failure is defined as recurrent dysplasia or BE on histology even if these patients then went on to have additional endotherapy.
Gastroenterology  , 87-95DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
KM analysis for durability of CR-D and CR-BE after successful ablation in patients who underwent focal ablation alone during the treatment protocol. Time 0 represents the first biopsy demonstrating no dysplasia or no BE and failure is defined as recurrent dysplasia or intestinal metaplasia on histology even if these patients then went on to have additional endotherapy.
Gastroenterology  , 87-95DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

5. Figure 4
Cumulative cancer risk in all patients (n = 335) completing treatment protocol with RFA for Barrett's neoplasia. The KM estimates the 5-year cancer risk at 8%.
Gastroenterology  , 87-95DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

6. Figure 5
Association of baseline Barrett's maximum length and number of RFA treatment sessions to attain successful CR-D, shown as mean ± SE.
Gastroenterology  , 87-95DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions